Here are five notes:
1. Exactech shares outperformed the S&P 500 by 5.45 percent last week and underperformed the index by 2.13 percent in the last four weeks.
2. The shares presently have a recommendation consensus of “buy.”
3. The company’s shares dropped 14.49 percent during the last three-month period and dropped 23.62 percent in the past 52 weeks.
4. The shares are projected to reach $22.50 in the short-term with the standard deviation of short-term price estimate valued at 0.71.
5. The target price is expected to hit $23 on the higher end and $22 on the lower end.
More articles on devices:
FTC final order preserves competition: 5 things to know about Zimmer’s acquisition of Biomet
Aurora Spine, LDR, SeaSpine & more — 12 key notes
OsteoMed Spine launches PrimaLIF LLIF System: 4 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
